Sana Biotechnology Outlines Pipeline Prioritization, Reduces Workforce

  • Sana Biotechnology Inc SANA announced a portfolio prioritization expected to provide a cash runway into 2025. 
  • The resulting changes include focusing its second HIP-modified allogeneic CAR T program on targeting CD22 for CD19 CAR T failures, halting further internal investment in its SC187 program (cardiomyocytes for heart failure), and stage-gating certain platform investments based upon clinical progress in humans. 
  • The prioritization and restructuring reduced the company's headcount by approximately 15%.
  • Related: Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies.
  • Sana remains on track to file an IND this year for SC291 (HIP-modified, CD19-targeted allogeneic CAR T), with initial clinical data expected in 2023. 
  • For SC263 and SG295, Sana expects to file an IND in 2023. 
  • For SC451 (HIP-modified, stem-cell derived pancreatic islet cell therapy for patients with type 1 diabetes) and SC255 (HIP-modified, BCMA-targeted allogeneic CAR T) for multiple myeloma, the company will file an IND in 2024. 
  • Price Action: SANA shares closed at $4.71 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!